Search results
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Jun 24, 2024 · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global...
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
Jun 24, 2024 · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Products. Over the years, Biocon Biologics has grown into a leading global biosimilars player, enabling affordable access to life-saving medicines and transforming patients’ lives across the world.
Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
Jun 24, 2024 · Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept. The company expects to include 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. ...
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines. We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Biocon Biologics offers one of the industry’s widest and deepest biosimilars portfolios, including monoclonal antibodies, insulin and insulin analogs and conjugated recombinant proteins.
